All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Cancer drug company AVEO Pharmaceuticals Inc. is partnering a preclinical antibody program with Schering-Plough Corp. for worldwide development and commercialization in a deal that could be worth up to $477.5 million. (BioWorld Today)